Adefovir
Clinical data | |
---|---|
Trade names | Hepsera |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 59% |
Protein binding | <4% |
Elimination half-life | 7.5 hours |
Excretion | Urine |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Adefovir is a prescription medicine used to treat (chronic) infections with hepatitis B virus. A prodrug form of adefovir was previously called bis-POM PMEA, with trade names Preveon and Hepsera. It is an orally administered nucleotide analog reverse-transcriptase inhibitor (ntRTI). It can be formulated as the pivoxil prodrug adefovir dipivoxil.
Uses
It is used for treatment of hepatitis B.[1][2][3][4]
Trials of adefovir in patients with HIV have not shown any clear benefits.[3][5]
History
Adefovir was invented in the Institute of Organic Chemistry and Biochemistry,
Gilead Sciences discontinued its development for HIV treatment in December 1999, but continued to develop the drug for hepatitis B (HBV), where it is effective with a much lower dose of 10 mg. FDA approval for use in the treatment of hepatitis B was granted on September 20, 2002, and adefovir is sold for this indication under the brand name Hepsera. Adefovir became an approved treatment for HBV in the European Union in March 2003.[citation needed]
Mechanism of action
Adefovir works by blocking
The main benefit of adefovir over lamivudine (the first NRTI approved for the treatment of HBV) is that it takes a much longer period of time for the virus to develop resistance to it.
Adefovir dipivoxil contains two pivaloyloxymethyl units, making it a prodrug form of adefovir.
References
External links
- CID {{{1}}} from PubChem - Adefovir dipivoxil